沙美特罗替卡松干粉剂吸入治疗支气管哮喘的疗效观察  

The Clinical Effects of Salmeterol and Fluticasone Propionate Dry Powder Inhalation on Asthma

作　　者：张琼[1] 黎英 

机构地区：[1]郫县人民医院,四川郫县611730 [2]成都市五冶医院,四川成都610031

出　　处：《昆明医学院学报》2009年第9期128-130,共3页Journal of Kunming Medical College

摘　　要：目的比较沙美特罗替卡松干粉剂(SM/FP)与单独吸入丙酸氟替卡松(FP)治疗中度持续哮喘的疗效.方法42例中度持续哮喘患者分为两组:治疗组(23例)吸入SM/FP50/250μg,每日早晚各1次;对照组(21例)吸入FP125μg每日早晚各1次.两组均治疗12周.观察晨间最大呼气峰流速值(PEFam)、晚间最大呼气峰流速值(PEFpm)、昼夜间哮喘症状、吸入沙丁胺醇气雾剂次数及FEV1变化.结果治疗前昼夜间哮喘症状、吸入沙丁胺醇气雾剂次数、PEFam、PEFpm及FEV1差异无显著性,吸入SFC治疗后第2周上述观察指标有明显改善,两组比较差异有统计学意义(P<0.05),在随后的第4,8,12周,上述指标持续好转(P<0.05).两组患者耐受性均较好,不良反应发生率低,症状轻微,差异无统计学意义(P>0.05).结论对于改善中度持续支气管哮喘患者症状和肺功能,联合吸入糖皮质激素和长效β2受体激动剂较单一吸入β2受体激动剂效果更佳.Objective To compare the effects of salmeterol and fluticasone propionate dry powder （SM/FP） and a separate inhaled fluticasone propionate （FP） on moderate persistent asthma. Methods 42 cases of moderate persistent asthma were divided into two groups：Treatment group （23 cases） , inhalation of SM/FP 50/250 μg, one time every morning and evening; the control group （21 cases） , FP 125 μg inhaled one times every morning and evening. The two groups were treated for 12 weeks. We observed the biggest morning peak expiratory flow values （PEFam） , the largest evening peak expiratory flow values （PEFpm） , asthma symptoms between day and night, inhaled salbutamol aerosol number and FEV1 changes. Results There was no significant difference Before treatment asthma symptoms between day and night, inhaled salbutamol aerosol number, PEFam, PEFpm and FEV1, 2 weeks after SFC treatment, we observed the above-mentioned indicators were markedly improved, there was a significant difference between the treatment group and control group （P 〈 0.05） , in the subsequent section 4, 8, 12 weeks observation period, the indicators continued to improve （P 〈 0.05）. Patients in the two groups were well tolerated, with low incidence of adverse reactions, mild symptoms, there was no significant difference between the two groups （P 〉 0.05）. Conclusion Persistent asthma symptoms and lung function, Combination of inhaled glucocorticoids and long-acting β 2 agonist is between than a single inhalation of β 2 agonists in improving the symptoms and lung function of patients with moderate persistent asthma.

关 键 词：哮喘 糖皮质激素 B 2受体激动剂 吸人治疗 

分 类 号：R562.25[医药卫生—呼吸系统]